ASH 2022 Conference Coverage
M

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
1,053 views
February 1, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

06:00
2024 Clinical Case Studies

Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration

Feat. A. Geisler
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
13:34
EULAR 2023 Insights

EULAR 2023 Insights: From Pathogenesis to Therapy in Sjögren's …

Feat. H. Bootsma
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips